Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Cemdisiran in Adult Patients with IgA Nephropathy
2018-002716-27Phase 2Unknown
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Jan 2019
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in IgA nephropathy (IgAN) comparing Cemdisiran with Placebo (2 arms). Primary endpoint: Percent change from baseline in urine protein/creatinine ratio in 24-hour urine at Week 32. Status: unknown.
02
Drugs
cemdisiran
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2018-002716-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002716-27.